Home » Eli Lilly Reconciles Zyprexa Inquiries for $62 Million

Oct

13

Eli Lilly Reconciles Zyprexa Inquiries for $62 Million

Posted by Editor | Posted in Defective Drugs

Last week, super-sized drugmaker, Eli Lilly & Co., cleared problems with its top selling drug Zyprexa, an anti-psychotic medication, by paying out $62 million to 32 states and Washington, D.C.

Eli Lilly was charged with marketing the drug for off-label uses, such as pediatric care and treatment of dementia, and not properly disclosing the full range of side effects to healthcare providers.

The company didn’t acknowledge any wrongdoing. The settlement will be divided among the states based on population.

According to the Indiana attorney general, the company also agreed to appropriate its medical staff (not its marketing staff) with the responsibility for consenting to the content in “all medical letters and medical references regarding Zyprexa.”

“The one thing that’s really key here is they’ve agreed to have a much more transparent system,” the attorney general said.

Check out Total Injury’s related articles:

 

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google

0

Post a comment

Disclaimer: The content found on the TotalInjury Blog is not legal advice and is purely for informational purposes. Total Injury, Inc. does not guarantee the accuracy, integrity or quality of submissions. The information provided by the bloggers on this site may not represent the opinions of the site editor(s), Total Injury, Inc. or its affiliates. The information contained herein is not a substitute for the advice of an attorney. For additional disclaimers, please visit our Terms & Conditions. All photos are of models and do not depict clients.